Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
13.79
+0.11 (0.80%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.

It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.

The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.

In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry.

Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks.

It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians.

Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health Incorporated
Elanco Animal Health logo
CountryUnited States
Founded1954
IPO DateSep 20, 2018
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees9,450
CEOJeffrey Simmons

Contact Details

Address:
2500 Innovation Way
Greenfield, Indiana 46140
United States
Phone877 352 6261
Websiteelanco.com

Stock Details

Ticker SymbolELAN
ExchangeNYSE
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001739104
CUSIP Number28414H103
ISIN NumberUS28414H1032
Employer ID82-5497352
SIC Code2834

Key Executives

NamePosition
Jeffrey N. SimmonsPresident, Chief Executive Officer and Director
Dr. Ramiro Martin CabralExecutive Vice President and President of Elanco International
Todd S. Young J.D.Advisor
Dr. Ellen de Brabander Ph.D.Executive Vice President of Research, Development and Regulatory Affairs
Timothy J. BettingtonExecutive Vice President of Corporate Strategy and Market Development
Robert M. VanHimbergenExecutive Vice President and Chief Financial Officer
James M. MeerSenior Vice President and Chief Accounting Officer
Chris KeeleySenior Vice President and Chief Information Officer
David S. KinardExecutive Vice President of Human Resources, Corporate Communications and Administration
Shiv O'NeillExecutive Vice President, General Counsel and Corporate Secretary

Latest SEC Filings

DateTypeTitle
Jun 26, 20258-KCurrent Report
May 30, 2025SDForm - SD
May 28, 20258-KCurrent Report
May 21, 20258-KCurrent Report
May 7, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
Apr 22, 2025SCHEDULE 13G/AFiling
Mar 27, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 27, 2025DEF 14AOther definitive proxy statements
Mar 17, 20258-KCurrent Report